AMRX Amneal Pharmaceuticals, Inc.
Company Analysis
Latest News
🟢 Amneal Pharmaceuticals is trading 4.65% up today amid stronger market sentiment
Amneal Pharmaceuticals is trading at $17.43, up +4.65%, amid stronger market sentiment. - No major company-specific announcement dated September 16, 2026 was...
🟢 Amneal Pharmaceuticals is trading 4.35% up today in pre-market; no confirmed catalyst identified
Amneal Pharmaceuticals is trading 4.35% up at $17.75, versus the provided September 11, 2026 close of $17.01, with no fresh, clearly attributable...
🟢 Amneal Pharmaceuticals is trading 6.32% up in pre-market with no clear company-specific catalyst
Amneal Pharmaceuticals is trading 6.32% up now at $19.00 in pre-market on September 4, 2026; no fresh company-specific announcement clearly explains the...
🟢 Amneal Pharmaceuticals is trading 4.1% up in after-hours trading amid broader risk-on market strength
Amneal Pharmaceuticals is trading at $18.65, up +4.13%, after broader risk-on market strength on August 21, 2026, with the S&P 500, Nasdaq Composite, and Dow...
🟢 Amneal Pharmaceuticals is trading 4.34% up today — no clear company-specific catalyst identified
Amneal Pharmaceuticals is trading 4.34% up at $18.02, with no clear company-specific catalyst identified for August 14, 2026. - Recent support may reflect...
🟢 Amneal Pharmaceuticals is trading 4.23% up in pre-market with no clear company-specific catalyst identified
Amneal Pharmaceuticals is trading at $18.00 (+4.23%), based on the supplied pre-market quote; no clear August 14, 2026 company-specific catalyst was identified...
🔴 Amneal Pharmaceuticals is trading 4.08% down today after completing Kashiv acquisition with new-share dilution
Amneal Pharmaceuticals is trading at $17.15, down -4.08%, after completing its Kashiv BioSciences acquisition, the clearest company-specific catalyst despite...
Amneal Pharmaceuticals Completes Acquisition of Kashiv BioSciences for $375M Cash and Stock
Amneal Pharmaceuticals, Inc. announced the completion of its acquisition of 100% of the membership interests in Kashiv BioSciences, LLC on August 10, 2026. The...
🟢 Amneal Pharmaceuticals is trading 5.5% up today on a raised 2026 outlook and Kashiv BioSciences acquisition
Amneal Pharmaceuticals is trading 5.5% up today at $19.32 after its July 30, 2026 earnings call highlighted a raised 2026 revenue outlook and a strategic pivot...
Amneal Pharmaceuticals Stockholders Approve Acquisition of Kashiv BioSciences
Amneal Pharmaceuticals (AMRX) announced that its stockholders have approved all necessary proposals related to its planned acquisition of 100% of the...
🟢 Amneal Pharmaceuticals is trading 8.9% up today after raising 2026 guidance and beating Q2 estimates
Amneal Pharmaceuticals is trading at $20.15 (8.9% up) after reporting strong second-quarter results and raising its 2026 financial outlook. • The company...
🔴 Amneal Pharmaceuticals is trading 5% down today following a multi-day rally into its Q2 report
Amneal Pharmaceuticals is trading 5% down at $18.15 today as the stock pulls back from a multi-day rally despite reporting strong second-quarter 2026...
Amneal Beats Estimates and Raises the Bar for 2026 — But Can It Outrun Its Debt Load and Deliver on a Billion-Dollar Biosimilar Bet?
Shares of Amneal Pharmaceuticals surged 7.3% to $20.49 in pre-market trading Thursday after the generic-drug maker posted second-quarter results that handily...
🟢 Amneal Pharmaceuticals is trading 10.1% up today after beating Q2 expectations and raising full-year 2026 guidance
Amneal Pharmaceuticals is trading 10.1% up at $21.02 following a strong Q2 2026 earnings report and an upward revision to its annual outlook. • The company...
🟢 Amneal Pharmaceuticals is trading 7.3% up today after beating Q2 estimates and raising guidance
Amneal Pharmaceuticals is trading at $20.49 (7.3% up) following a strong second-quarter earnings report and an improved financial outlook. • Net revenue grew...
Amneal Pharmaceuticals posts strong second quarter with 10% revenue growth, raising its full-year 2026 guidance.
Amneal Pharmaceuticals reported second quarter 2026 net revenue of $796 million, up 10% year-over-year, and GAAP diluted EPS of $0.18. The company's adjusted...
Amneal Pharmaceuticals, Inc. Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Amneal Pharmaceuticals is projected to report Q2 2026 consensus revenue of $762.5 million and EPS of $0.24, with the current stock price of $14.12 sitting...